AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05899153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Biofeedback
Description: Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
Study NCT05230940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TURKOVAC
Description: Inactive COVID-19 Vaccine - TURKOVAC
Study NCT05230940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: It has 600 subunit of SARS-CoV-2 virus antigen
Study NCT04120285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: remote internet-based cognitive behavior therapy (eCBT)
Description: Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
Study NCT05361395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab will be administered as an intravenous (IV) infusion.
Study NCT05361395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an intravenous (IV) infusion.
Study NCT05361395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered as an intravenous (IV) infusion.
Study NCT05361395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as an intravenous (IV) infusion.
Study NCT05361395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered as an intravenous (IV) infusion.
Study NCT05188586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI/Imaging
Description: Blood collection and pancreatic cancer early detection testing with return of results.
Study NCT06579768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: different types of computed tomography (CT) scans
Description: For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.
Study NCT04742556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441
Study NCT05108246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Exercise Training
Description: Simultaneous cognitive-motor training
Study NCT06584539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eco-Labels
Description: Eco-labels will be displayed next to more sustainable restaurant menu items. The labels will display an earth icon and the words ENVIRONMENTALLY FRIENDLY.
Study NCT04993859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive Urodynamic Test (niUDS)
Description: A noninvasive urodynamics is a simple test used to evaluate urinary flow.
Study NCT04993859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary proteomic screen
Description: Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
Study NCT04993859 — intervention group
Intervention type: OTHER
Intervention: Dysfunctional Voiding Symptom Score Survey (DVSS)
Description: The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
Study NCT05746611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium tuberculosis fusion protein for injection
Description: For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
Study NCT05746611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB-PPD was injected
Description: For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
Study NCT05766397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane
Description: Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
Study NCT06475664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized legal care services
Description: Participants will receive free, personalized legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota. The duration of study participation is 6 months, however, participants may continue to access free personalized legal care services beyond this period.
Study NCT05397717 — intervention group
Intervention type: OTHER
Intervention: observational
Description: Observational, without interfering the patient care of treating doctors
Study NCT06448273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3702 tablets
Description: TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
Study NCT06448273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB3702 placebo
Description: TQB3702 placebo contains no active substance.
Study NCT06279026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UTAA17 Injection
Description: After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
Study NCT06352723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7
Study NCT06150040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137
Description: IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
Study NCT06150040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
Study NCT06150040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally, 70 mg, every day on Days 1-28
Study NCT05147220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: tablet taken orally
Study NCT05147220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: capsule taken orally
Study NCT04918420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Diverter (Tonbridge)
Description: The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
Study NCT05671107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NET
Description: Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
Study NCT06547827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic rehabilitation
Description: Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients.
Study NCT06547827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients.
Study NCT05644119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V- loop Bonded Orthodontic Retainer
Description: The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
Study NCT05644119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straight Wire Retainer
Description: The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
Study NCT06122688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator Plus App Intervention
Description: Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
Study NCT06270888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation given for cancer treatment. Radiation is usually an outpatient procedure completed over the course of 1-6 weeks. High-energy radiation will be delivered to a focused area of the body using a treatment machine called a linear accelerator. Unlike surgery, there are no invasive procedures other than inserting an IV during the radiation planning session. Radiation uses a mold that is customized to fit your body. This mold will be made in the radiation planning session and be used during treatment to keep you from moving. The mold is necessary for very accurate targeting of your tumor. During the procedure, the radiation therapy team will also confirm the exact location that needs to be treated using x-rays.
Study NCT04790474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib-pomalidomide-dexamethasone
Description: Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
Study NCT05101590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitored by HDA
Description: Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
Study NCT04913610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-4083
Description: Oral Capsule
Study NCT04913610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-4083
Description: Oral Capsule
Study NCT04913610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Oral encapsulated tablets
Study NCT04913610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Albendazole
Description: Oral Capsule
Study NCT05665036 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIG-005 (hIDUA Producing Spheres)
Description: Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
Study NCT05831033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEN101
Description: Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur.
Study NCT04519008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Medical device for improving emotion dysregulation
Study NCT04519008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Bimonthly individual psychotherapy and psychostimulant medications
Study NCT04519008 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Bimonthly individual psychotherapy and psychostimulant medications
Study NCT06329440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurement of diaphragm thickness
Description: Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
Study NCT04923867 — intervention group
Intervention type: DEVICE
Intervention: Suturable DuraGen™
Description: Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
Study NCT05748275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Argos
Description: Biometry measurements first with the Argos device, then the IOLMaster 700 device.
Study NCT05991843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions of breathing
Description: Breathing normally, slowly and rapidly for 30 seconds with an open and a closed mouth.
Study NCT06216873 — intervention group
Intervention type: OTHER
Intervention: multiple trauma
Description: Review the medical record to gather the physical parameters, blood examination result and radiologic examination results
Study NCT05333679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UTRA
Description: Collect urine on intervention participants and screen for presence of TFV.
Study NCT05333679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UTRA feedback
Description: Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
Study NCT04688502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
Study NCT04688502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
Study NCT04688502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Description: 5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
Study NCT04688502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise training
Description: 5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
Study NCT05027997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipraglurant
Description: Oral tablet
Study NCT05027997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo tablet
Study NCT06203366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vojta therapy
Description: Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
Study NCT05370001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entotracheal tube size
Description: Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
Study NCT05721404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin Peritoneal Dialysis Solution
Description: Icodextrin (Extraneal) for long night dwell
Study NCT05748275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOLMaster 700
Description: Biometry measurements first with the IOLMaster 700 device, then the Argos device.
Study NCT04197700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Target MAP Management
Description: Target MAP Management
Study NCT04913272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-APR2020
Description: US-APR2020 capsules 45 billion CFUs of the LBT.
Study NCT04913272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04441307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Foundations
Description: Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
Study NCT04441307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Foundations
Description: A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
Study NCT05607407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methimazole
Description: Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
Study NCT05607407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recurrent Glioblastoma Surgical Resection
Description: The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
Study NCT05607407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Assays
Description: Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
Study NCT04506853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MED-EL Cochlear Implant System
Description: Cochlear implant and audio processor
Study NCT05721404 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hypertonic Dextrose solution
Description: Hypertonic Dextrose solution for long night dwell
Study NCT04949191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib tablets taken by mouth once daily as per protocol
Study NCT04949191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
Study NCT04949191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Commercially labeled products
Study NCT05632653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO-PCI
Description: Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).
Study NCT05574322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive foot strengthening protocol
Description: This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~* Maximum muscle strength of the foot~* Foot muscle morphology
Study NCT05574322 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
Study NCT05714267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise cancelling
Description: During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
Study NCT05714267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive noice cancelling
Description: During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.